All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

December 5th 2023

The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.

FDA Grants Priority Review to Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma

December 5th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.

Westin Testifies to Senate Finance Committee on Cancer Drug Shortage

December 5th 2023

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

AEGEAN Subgroup Analysis Fails to Demonstrate Clear Benefit With Perioperative Durvalumab Plus Chemo in EGFR+ NSCLC

December 5th 2023

David Harpole, MD, discusses key data from the first interim analysis of the AEGEAN trial, changes to the adjuvant treatment landscape that inspired the subgroup analysis of patients with EGFR mutations excluded from the intention-to-treat population, and more.

Florida Cancer Specialist Optimizing Use of Anticancer Drugs to Improve Care for Patients with Blood Disorders

December 5th 2023

A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.

FDA Grants Breakthrough Device Designation to Assay for ACR-368 in Ovarian Cancer

December 5th 2023

The FDA granted breakthrough device designation to the ACR-368 OncoSignature assay for the identification of patients with ovarian cancer who may derive benefit from the CHK1/2 inhibitor ACR-368.

New Developments in MPN Management Provide Additional Options for Patients

December 5th 2023

Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

December 5th 2023

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

December 4th 2023

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

BDTX-1535 Strives to Overcome Intrinsic and Acquired EGFR Mutations in NSCLC and GBM

December 4th 2023

Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

December 4th 2023

The FDA has granted a fast track designation to BI 764532 for use as a therapeutic option in patients with advanced or metastatic DLL3-expressing large-cell neuroendocrine carcinoma of the lung who experienced disease progression after treatment with 1 or more lines of therapy, including platinum-based chemotherapy.

ADC Doublets Represent a Promising Novel Approach for Treatment-Resistant mUC

December 4th 2023

Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.

Sylvester Physician Elected to Society for Neuro-Oncology Board of Directors

December 4th 2023

Macarena de la Fuente, MD, becomes the first Hispanic elected and will represent neurology on the multidisciplinary board.

TKI and Immunotherapy Combo Efforts in RCC Remain of Interest as Treatment Arsenal Evolves

December 4th 2023

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Ovarian Cancer Research Outlines the Role of ADCs, PARP Inhibitors, and Surgery

December 4th 2023

Hope Cottrill, MD, highlights key points that were presented at a State of the Science Summit meeting, including the role of bevacizumab plus PARP inhibitors in ovarian cancer management, how to manage adverse events associated with antibody-drug conjugates, and ongoing research in ovarian cancer risk reduction.

Florida Cancer Specialists & Research Institute Appoints Richard McDonough, MD Director of Patient Advocacy

December 3rd 2023

Florida Cancer Specialists & Research Institute, LLC has appointed medical oncologist and hematologist Richard McDonough, MD as Director of Patient Advocacy for the statewide practice.

Neoadjuvant Chemotherapy Does Not Give Survival Benefit Over Chemoradiation in Cervical Cancer

December 3rd 2023

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

FCS Launches Advanced Cellular Therapy Program to Treat Recurring Blood Cancers

December 2nd 2023

Florida Cancer Specialists & Research Institute, LLC is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma.

Adding Pemetrexed to Cisplatin Does Not Result in Survival Benefit Over Vinorelbine in NSCLC

December 2nd 2023

Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

December 1st 2023

The FDA has granted an accelerated approval to pirtobrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.